Abstract
ABSTRACT
 Aim: The management of testicular cancer (TC) requires more specific and applicable biomarkers. We aimed to determine the ability of complete blood count (CBC) based inflammatory markers to predict tumor pathology and prognosis in TC.
 
 Methods: Patients who underwent inguinal orchiectomy for testicular germ cell tumors (TGCTs) at our hospital between June 2016 and August 2022 were included in the study. The medical records of patients with pathologically confirmed TC, including demographics, preoperative tumor markers, preoperative CBC, tumor characteristics, pathological outcomes, postoperative follow-up, and survival outcomes, were retrospectively collected. CBC-based inflammatory markers were compared between seminomatous and non-seminomatous TGCTs. Overall survival and disease-free survival were analyzed using the Kaplan-Meier method. Other associated prognostic variables were assessed using univariate and multivariate Cox regression analyses.
 
 Results: The median follow-up was 48 (6-206) months. In our chord, 69 patients had seminomatous TGCTs (Group 1), and 66 had non-seminomatous TGCTs (Group 2). The median ages of Groups 1 and 2 were 35 (22-74) years and 31 (21-72) years, respectively. The median platelet count (PC) was 238 (136.2-376.6) 10³/mm³ in Group 1, and 260.5 (256-414) 10³/mm³ in Group 2 (p
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
